key: cord-0701838-7g3keqx9
authors: Zhang, H.; Zhao, Y.; Jiang, X.; Li, Y.; Li, C.; Dong, M.; Luan, Z.; Yan, C.; Jiao, J.; Zhao, C.; Li, H.; Chen, W.; Feng, C.; Tian, L.; Qin, E.; Mu, J.; Zeng, T.; Feng, S.; Wang, S.; Guan, X.; Li, T.; Yu, H.; Zheng, A.; Jin, W.; Sun, G.
title: Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study
date: 2020-05-15
journal: nan
DOI: 10.1101/2020.05.11.20064584
sha: 7712758b4ef86ab8fedea1806da58de6b75a318c
doc_id: 701838
cord_uid: 7g3keqx9

Background& Aims: The Coronavirus Disease 2019 (COVID-19) has become a global epidemic and has caused a lasting and huge loss of life security, economic development and social stability in more than 180 countries around the world. Unfortunately, there is still no specific treatment for COVID-19 till now, therefore, at this point, all potential therapies need to be critically considered. LL-37 is one of the best-studied human antimicrobial peptide (AMPs) that has a broad-spectrum activity against bacteria and viruses. The use of living, genetically modified organisms (GMOs) is an effective approach for delivery of therapeutic proteins. The aim of this study was to determine the safety and efficacy of the Lactococcus lactis which has been genetically modified to produce the therapeutic human antimicrobial peptide LL-37 (herein after referred to cas001) in the patients of COVID-19. Methods: Firstly we constructed genetically modified food-grade probiotic, Lactococcus lactis, with sequence of seven tandem repeats of mature human LL-37 under control of the nisin-inducible nisA promoter to produce the cas001. A total of 20 healthy SD rats, half male and half female (There were five male and five female in the control group, the same in treatment group) were used to observe the acute toxic reaction and death after daily administration of cas001 for three weeks, which helps to provide necessary reference basis for clinical dose selection, verificaition of toxic reaction and possible target organs. According to the estimated clinical dosage of 1 x 108CFU /kg/day, considering the conversion of body surface area, the dose for rats should be multiplied by 6.17 to 6 x 108 CFU/kg/day. We administrated 100 times higher dose at 6 x 1010 CFU/kg/day to rats. In order to investigate the pharmacokinetics of cas001, male SD rats (body weight 250-300g, 1 x 1010 /animal, n=3) were given oral administration of LL-37 bacteria powder. The concentration of LL-37 in the blood before and after gavage was detected by ELISA kit (Hycult biotechnology Cat# HK321). Human clinical study was approved by Ethics committee of Chinese PLA General Hospital (S2020-074-04) and a total of 11 patients with mild symptoms were enrolled in Wuhan hankou hospital and Huoshenshan hospital. They were enrolled voluntarily and all patients signed informed consent. Among them, there were 5 males and 6 females, aged 55 {+/-} 12 (36-70) years old, and the duration from onset to medication enrollment was 35 {+/-} 19 (5-68) days. 6 patients were nucleic acid positive and 5 patients were nucleic acid negative when they were enrolled. All patients received the oral drug cas001 treatment according to requirement(1 x 109 CFU/capsule, 3 capsules/time, three times a day for 3weeks), with an average follow-up time of 33 {+/-} 15 days (see table 1 for the results). Findings: Western blot analysis shows that reasonable amount of LL-37 were induced by different concentrations of nisin, which means we have successfully constructed cas001. In the pre-clinical safety evaluation test, after three weeks administration of cas001, no adverse effects were observed on the rat's body weight, food and water intake, hematological or serum biochemical parameters. The results showed that the LD50 of cas001 was higher than that of the 100 times of the expected clinical dose of 6 x 1010 CFU/day. These results showed that cas001 could be safe in animal experiments. In addition, rat pharmacokinetics results showed that the serum concentration of LL-37 reached peak 2 hours after gavage of cas001 and returned to basal level 6 hours after gavage. During study period, the volunteers did not feel any discomfort while taking the cas001 capsules, and two hours after oral administration, the concentration of LL-37 were increased in healthy volunteers. cas001 shows definite effect in the improvement of gastrointestinal symptoms and is possible to have effects in improving the systemic symptoms and respiratory symptoms and may play a role in the improvement of results of nucleic acid test and lung CT test. 11 patients enrolled showed good compliance, tolerance, subjective feeling and actively interacted with the doctors. None of the patients had any adverse reactions. Conclusions Based on above observations, we conclude here that as an oral anti-viral agent, cas001 displayed good safety profiles. It is very hard to reach conclusion of clinical outcomes related to the cas001, although changes of several symptoms indicate encouraging findings.

Background& Aims: 2 The Coronavirus Disease 2019 (COVID-19) has become a global epidemic and has caused a 3 lasting and huge loss of life security, economic development and social stability in more than 180 4 countries around the world. Unfortunately, there is still no specific treatment for COVID-19 till now, 5 therefore, at this point, all potential therapies need to be critically considered. LL-37 is one of the 6 best-studied human antimicrobial peptide (AMPs) that has a broad-spectrum activity against 7 bacteria and viruses. The use of living, genetically modified organisms (GMOs) is an effective 8 approach for delivery of therapeutic proteins. The aim of this study was to determine the safety and 9 efficacy of the Lactococcus lactis which has been genetically modified to produce the therapeutic 10 human antimicrobial peptide LL-37 (herein after referred to cas001) in the patients of Methods: 12 Firstly we constructed genetically modified food-grade probiotic, Lactococcus lactis, with sequence 13 of seven tandem repeats of mature human LL-37 under control of the nisin-inducible nisA promoter 14 to produce the cas001. A total of 20 healthy SD rats, half male and half female (There were five 15 male and five female in the control group, the same in treatment group) were used to observe the 16 acute toxic reaction and death after daily administration of cas001 for three weeks, which helps to 17 provide necessary reference basis for clinical dose selection, verificaition of toxic reaction and 18 possible target organs. According to the estimated clinical dosage of 1 x 10 8 CFU /kg/day, 19 considering the conversion of body surface area, the dose for rats should be multiplied by 6.17 to 6 20 x 10 8 CFU/kg/day. We administrated 100 times higher dose at 6 x 10 10 CFU/ /kg/day to rats. In 21 order to investigate the pharmacokinetics of cas001, male SD rats (body weight 250-300g, 1 x 10 10 22 /animal, n=3) were given oral administration of LL-37 bacteria powder. The concentration of LL-37 23 in the blood before and after gavage was detected by ELISA kit (Hycult biotechnology Cat# 24 HK321).

Human clinical study was approved by Ethics committee of Chinese PLA General Hospital 27 (S2020-074-04) and a total of 11 patients with mild symptoms were enrolled in Wuhan hankou 28 hospital and Huoshenshan hospital. They were enrolled voluntarily and all patients signed informed 29 consent. Among them, there were 5 males and 6 females, aged 55 ± 12 (36-70) years old, and the 30 duration from onset to medication enrollment was 35 ± 19 (5-68) days. 6 patients were nucleic acid 31 positive and 5 patients were nucleic acid negative when they were enrolled. All patients received 32 the oral drug cas001 treatment according to requirement(1 x 10 9 CFU/capsule, 3 capsules/time, 33 three times a day for 3weeks), with an average follow-up time of 33 ± 15 days (see table 1 for the 34 results).

On March 11, 2020, the director-general of World Health Organization (WHO) declared the severe 3 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) situation as a pandemic 1 . By May 4, 2020, 4 the number of cases of COVID-19 had increased exponentially. There have been more than 3 5 million reported cases, 240 thousand death and the number of affected countries was more than 6 200. Recent report has demonstrated that there is less than 80% sequence similarity between 7 SARS-CoV-2 and SARS-CoV 2 and recent studies also pointed to the important role of ACE2 in 8 mediating entry of SARS-CoV-2 2, 3 .

Currently, there is no specific treatment for COVID-19 and therapeutic options in response to the 11 COVID-19 outbreak are urgently needed 4, 5 . For above reasons, there are several options can be 12 considered for drug discovery: the first one is to screen anti-viral drugs that are approved by The purpose of this study was to determine the safety and efficacy of the cas001 in the treatment of 1 patients with COVID-19. week of adjustable feeding, male (n=10) and female (n=10) SD Rats were randomly separated into 14 equal-number-individual groups respectively according to body weight and treated with 15 6.0E10/kg· day frozen-dried powder by gavage in the animal safety assessment. In the following 16 two weeks, body weight, water drink, food intake, blood routine examination, serum biochemical 17 analysis and daily observation were recorded to assess the risk of drug. For pharmacokinetics 18 tracking, rats of same age were treated with same dose of recombinant bacteria (n=3), blood 19 samples were collected from tail tip at 0, 1, 2, 4, 6 hr after gavage. Serum LL-37 concentration were 20 detected by Hycult biotechnology human ELISA KIT (Cat# HK321).

Ethics 23 Animals were housed under a 12/12 hr light/dark cycle with free access to food and water. Before 24 sacrifice, animals were given an anesthetic and cervical dislocation rapidly to relieve pain. All Cell culture 43 The cas001 were cultured at 30℃ up to 9-10 hours in mixed M17 media (0.5% Soya peptone, 0.25% 44 peptone, 0.25% Casein peptone, 0.25% Yeast Extract, 0.5% Beef Extract, 0.05% Ascorbic acid, 1.9% 45 β-Disodium Glycerophosphate and 0.025% MgSO4· 7H2O, adjusted to pH 7.2, replenishing 0.5%

Lactose after being autoclaved before use) until the end of logarithmic growth phase. Before 47 vacuum freeze-drying, these probiotics were collected by centrifuging and mixed with 48 cryoprotectant (3.5% skim milk powder, 19.5% maltodextrin) in the right proportions for oral 49 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 15, 2020. . administration. Vero cell line, the courtesy of Aihua-Zheng, Ph.D, were cultured in DMEM high 1 medium with 8%FBS, at 37℃ and 5% CO2. The cas001 were taken out from ultra-low temperature refrigerator for overnight activation twice at 5 30 ℃ in M17 medium. Then the pure culture above was transferred into 10 ml fresh M17 medium 6 for stationary culture until OD600 was around 0.4-0.6, different concentrations of nisin was added 7 to induce the LL-37 fusion protein expression. Finally proteins in supernatant were concentrated by The research ethics committee of Chinese PLA General Hospital (S2020-074-04) approved the 31 study and all participants signed an informed consent according to the requirement of Ethics 32 As a food grade bacterial strains, lactococcus lactis was usually regarded as a very convenient 1 living oral drug carrier which could transport protein drugs or vaccines. Here we designed a 2 recombinant lactococcus lactis carrying LL-37(cas001), a human endogenous antiviral peptide to 3 treat COVID-19 (Fig. 1A) . In order to express the shorter target polypeptide, we combined signal 4 peptide, LEISS enhancing sequence with seven tandem repeated sequences encoding mature 5 human LL-37 under control of the nisin-inducible nisA promoter ( Fig. 1B-C) . The cas001 could 6 secrete target protein (~34KD) into supernatant followed by addition of inducer Nisin (Fig. 1D) . 7 Therefore we successfully constructed LL-37 over-expressing lactococcus lactis. significant difference between the treatment group and the control group (Fig. 3C) , indicating that 1 the oral cas001 did not affect the weight gain. During the observation period, the food intake, water 2 intake, organs weight and histological examination results of SD rats in treatment group were not 3 significantly different from those of the control group (Fig. 3D-G) , indicating that under this 4 experimental condition, cas001 did not affect the appetite of experimental animals. The results of 5 blood biochemistry examination indicated that there was no significant difference in liver, kidney 6 function, myocardial enzyme concentration, blood lipid concentration and electrolyte concentration 7 between the two groups of SD rats (all p values were > 0.05) (Table. 1) .

To assess pharmacokinetics in human individuals, four healthy adult volunteers were recruited to 10 the study (Table. 2). During dose escalation study periods, the volunteers did not feel any 11 discomfort while taking the cas001 capsules, such as fatigue, weakness, nausea, vomiting, etc. 12 Two hours after oral administration, the concentration of LL-37 level was increased in healthy 13 volunteers (#1volunteer who took highest dose of cas001, increased significantly, the others only 14 increased slightly) ( Table. 3). Accordingly, there was no significant change in liver and kidney 15 function after oral cas001 medication (Table. 4 ). All these results taken together, cas001 displays 16 an excellent safety profile in both preclinical trials and healthy volunteers assay. There is a report indicating that although gastrointestinal symptoms were uncommon, still a part of patient was in home isolation and did not receive reexamination. Whether the change of the nucleic 1 acid test results is related to cas001 is not easy to infer at present. In terms of the improvement of 2 lung CT results, 3 cases got completely improved and 1 case got 75% improved. It took 7days for 3 recovery from mild inflammation to complete absorption of inflammation. Whether the cas001 4 improves or accelerates healing process remains to be investigated. Overall, cas001 shows 5 definite effect in the improvement of gastrointestinal symptoms and is possible to have effects in 6 improving the systemic symptoms and respiratory symptoms and may play a role in the 7 improvement of results of nucleic acid test and lung CT test.

This study is limited to a small scope and mainly focuses on the safety exploration. The epidemic of 10 novel coronavirus in China is in the clearance phase, so the number of medical records included 11 from the above two centers is very limited. What's more, there are few clinical cases related to 12 cas001, which is a major defect of current clinical study. In addition, all patients were discharged 13 from the hospital 3-5 days after enrollment, and were isolated at home or in a quarantine place, Current study has several following limitations. Firstly, primary purpose of current clinical trial is 31 assessment of safety profiles. In this regard, we did not performed dose escalation study, therefore, 32 optimal clinical dose of cas001 is not yet fully determined. Secondly, this was a small scale single 

The authors declare no conflict of interest. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 15, 2020. 

COVID-19: towards controlling of a pandemic

Structure of the SARS-CoV-2 spike receptor-binding domain bound to 4 the ACE2 receptor

SARS-CoV-2 Cell Entry Depends on ACE2 6 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Race to find COVID-19 treatments accelerates

Pharmacologic Treatments for 10

COVID-19): A Review

Aldosterone System Inhibitors in Patients with Covid-19. The New England 13 journal of

Remdesivir and chloroquine effectively inhibit the recently 15 emerged novel coronavirus (2019-nCoV) in vitro

Chloroquine and hydroxychloroquine in covid-19

Compassionate Use of Remdesivir for Patients with Severe 19

The New England journal of medicine 2020

Antimicrobial host defence 21 peptides: functions and clinical potential